The SGLT2 Inhibitor Family

## Overview

SGLT2 inhibitors (gliflozins) are a breakthrough class in type 2 diabetes treatment, distinguished by their renal mechanism of action and cardioprotective effects that are at least partially independent of glucose lowering. They inhibit sodium-glucose cotransporter 2 (SGLT2) in the S1 segment of the renal proximal tubule, which reabsorbs approximately 90% of filtered glucose. Inhibition of SGLT2 causes selective glucosuria (~60–80 g glucose/day), reducing plasma glucose without insulin dependence. More significantly, landmark trials (EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, DAPA-HF) demonstrated reductions in heart failure hospitalizations, cardiovascular death, and progression of diabetic kidney disease—effects now recognized as extending beyond glucose lowering.

## C-Glucoside Innovation

The natural product phlorizin, an O-glucoside isolated from apple bark, was the first known SGLT inhibitor. However, phlorizin inhibits both SGLT2 and the intestinal SGLT1, causing osmotic diarrhea. More critically, O-glucosides are cleaved by intestinal lactase-phlorizin hydrolase and β-glucosidases, preventing oral bioavailability. The key synthetic innovation was replacing the O-glycosidic bond with a C-C bond (C-glucoside). C-glucosides are completely stable to glycosidases, enabling oral dosing. The C1-aryl β-C-glucoside scaffold is the defining motif of all clinical SGLT2 inhibitors.

## SGLT2 Binding Mode

SGLT2 (SLC5A2) is a sodium-dependent glucose transporter. Homology models and structures of the bacterial homolog vSGLT show that glucose-like ligands occupy a central binding cavity with multiple hydroxyl-coordinating residues (Gln170, Tyr287, Thr460) forming a hydrogen-bond network with the pyranose ring hydroxyls. The C1-aryl group of gliflozins extends into a hydrophobic "aglycone" pocket that is absent in SGLT1 (key to selectivity). The methyl or halogen substituents on the aryl rings contact hydrophobic residues in this pocket.

## Cardiorenal Effects: Mechanisms Beyond Glucose

Glucosuria-induced osmotic diuresis reduces preload and interstitial fluid, beneficial in heart failure. Natriuresis (sodium is co-transported with glucose) reduces tubuloglomerular feedback, lowering intraglomerular pressure. Systemic volume contraction and mild ketogenesis (glucagon-insulin ratio shift) may provide additional myocardial fuel. SGLT2 inhibitors also reduce uric acid and may have direct cardiac and renal effects through off-target mechanisms including SGLT1 in cardiomyocytes and direct inhibition of the sodium-hydrogen exchanger NHE1.

## SGLT1 vs SGLT2 Selectivity

SGLT1 is expressed in the intestinal brush border and the S3 segment of the renal proximal tubule, mediating ~10% of renal glucose reabsorption. Empagliflozin achieves the highest SGLT2 selectivity (>2,500-fold) through its bicyclic tetrahydrobenzofuran ("B-ring locked") distal extension. Canagliflozin, with a thienylmethylphenyl extension, also inhibits intestinal SGLT1, which independently reduces postprandial glucose absorption—a mechanism that may explain why canagliflozin slightly outperforms pure SGLT2 selectivity predictions.

## Key Takeaways

- C-glucoside replaces O-glucoside for oral metabolic stability; beta-configuration at C1 is required for SGLT2 binding
- 4'-Halogen on the proximal phenyl fills a lipophilic sub-pocket, enhancing potency and bioavailability
- Distal aryl/heteroaryl governs SGLT2 vs SGLT1 selectivity; thienyl bicyclics (empagliflozin) achieve highest selectivity
- Cardiorenal benefits extend beyond glucose lowering via diuresis, natriuresis, ketogenesis, and intraglomerular pressure reduction
- Canagliflozin's dual SGLT2/SGLT1 inhibition provides an additional postprandial glucose mechanism